P/B
5,1
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
$6B
Market Cap • 9/11/2026
2019
(7 years)
Founded
2023
(3 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
2325,4
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
25,1
EPS
—
Market Cap
Market Cap
6B
EV
5,1B
EV/Revenue
1982,7
EV/EBITDA
-23,5
EV/EBIT
-23,5
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-17,1%
Total Yield
-17,1%
Payout
0%
Retained Earnings
-427,8M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
6795,6%
Capex/Revenue
12,9%
Capex/D&A
271,5%
Capex/OCF
-0,2%
SBC/OCF
—
% PPE
0,1%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
24,2%
CAGR Net Income 5Y
22,3%
CAGR EPS 5Y
-28,9%
CAGR OCF 5Y
21,8%
Leverage
N.D./EBITDA
4,1
Debt/Equity
0%
Current Ratio
26,1
Quick Ratio
25,8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!